Coronavirus Notebook: Middle Ground Pricing As Moderna Reaches 100m Dose US Agreement
Plus, Evidence Accelerator Finds No Benefit With HCQ
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.
You may also be interested in...
President’s comments follow two revelations: Pfizer’s acknowledgement that it will not meet its previously-stated vaccine production goals for 2020, and the US government’s decide to pass on additional Pfizer doses which have since been allocated to other countries.
As China gears up to the possible launch of its first vaccines against the coronavirus, supported by clearer regulations, many see the candidates as promising and cost-effective, although they may need more convincing data to be widely adopted. Relatively low projected per dose costs are generating interest in trials in multiple countries.
Cigna's Steve Miller suggests pharma is taking a responsible approach to pricing during the pandemic in a policy discussion convened by the Institute for Clinical and Economic Review on pricing models for COVID-19 drugs and vaccines.